Prazitone
Chemical compound
- none
- 5-phenyl-5-(piperidin-2-ylmethyl)pyrimidine-2,4,6(1H,3H,5H)-trione
- 2409-26-9 Y
- 3050417
- 2312482 N
- 6DZB018428
- Interactive image
- C1CCNC(C1)CC2(C(=O)NC(=O)NC2=O)C3=CC=CC=C3
InChI
- InChI=1S/C16H19N3O3/c20-13-16(11-6-2-1-3-7-11,14(21)19-15(22)18-13)10-12-8-4-5-9-17-12/h1-3,6-7,12,17H,4-5,8-10H2,(H2,18,19,20,21,22) N
- Key:UGZAKKMLMJITLL-UHFFFAOYSA-N N
Prazitone (AGN-511) is a barbiturate derivative developed in the 1970s.[1] Unlike most barbiturates, it has little or no sedative effects, instead acting as a non-sedating anxiolytic and antidepressant.[2] The dosage range in humans is around 200–600 mg, although higher doses have been used in trials for the treatment of depression associated with Parkinson's disease.
References
- v
- t
- e
Antidepressants (N06A)
Specific reuptake inhibitors and/or receptor modulators | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
Miscellaneous | |
---|---|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This article about an anxiolytic is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e